CRO Services
Participate In a Study
About Us
Careers
Contact
FR
CRO Services
Participate In a Study
About Us
Careers
Contact
FR
Test
Post navigation
Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
